ATE502003T1 - L-(-)-moprolol-l-(+)-tartrat - Google Patents

L-(-)-moprolol-l-(+)-tartrat

Info

Publication number
ATE502003T1
ATE502003T1 AT05701093T AT05701093T ATE502003T1 AT E502003 T1 ATE502003 T1 AT E502003T1 AT 05701093 T AT05701093 T AT 05701093T AT 05701093 T AT05701093 T AT 05701093T AT E502003 T1 ATE502003 T1 AT E502003T1
Authority
AT
Austria
Prior art keywords
moprolol
tartrate
preparing
pharmaceutical composition
tartrate salt
Prior art date
Application number
AT05701093T
Other languages
English (en)
Inventor
Mario Pinza
Caterina Maugeri
Nicola Cazzolla
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Application granted granted Critical
Publication of ATE502003T1 publication Critical patent/ATE502003T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Detergent Compositions (AREA)
AT05701093T 2004-01-30 2005-01-14 L-(-)-moprolol-l-(+)-tartrat ATE502003T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000145A ITMI20040145A1 (it) 2004-01-30 2004-01-30 L-moprololo lpiu' tartrato
PCT/EP2005/000560 WO2005075408A1 (en) 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate

Publications (1)

Publication Number Publication Date
ATE502003T1 true ATE502003T1 (de) 2011-04-15

Family

ID=34835572

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701093T ATE502003T1 (de) 2004-01-30 2005-01-14 L-(-)-moprolol-l-(+)-tartrat

Country Status (19)

Country Link
US (1) US7524886B2 (de)
EP (1) EP1708987B1 (de)
JP (1) JP4646922B2 (de)
KR (1) KR101122173B1 (de)
CN (1) CN100480232C (de)
AT (1) ATE502003T1 (de)
AU (1) AU2005211458B2 (de)
BR (1) BRPI0507150A (de)
CA (1) CA2550302C (de)
DE (1) DE602005026908D1 (de)
DK (1) DK1708987T3 (de)
EA (1) EA200601402A1 (de)
ES (1) ES2361518T3 (de)
IL (1) IL176280A (de)
IT (1) ITMI20040145A1 (de)
PL (1) PL1708987T3 (de)
PT (1) PT1708987E (de)
SI (1) SI1708987T1 (de)
WO (1) WO2005075408A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1211589A (en) * 1968-08-06 1970-11-11 Ici Ltd Enantiomer isolation process
IT1113029B (it) * 1979-03-01 1986-01-20 Simes Processo per la separazione dei due isomeri ottici del moprololo e composizioni farmaceutiche dell'antipodo levogiro
IT1163107B (it) * 1983-02-15 1987-04-08 Simes Composizioni farmaceutiche e loro uso nel trattamento del glaucoma
DE3544172A1 (de) * 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos

Also Published As

Publication number Publication date
CN1910138A (zh) 2007-02-07
US7524886B2 (en) 2009-04-28
KR20070000451A (ko) 2007-01-02
DK1708987T3 (da) 2011-06-27
CA2550302A1 (en) 2005-08-18
DE602005026908D1 (de) 2011-04-28
AU2005211458B2 (en) 2010-06-24
CA2550302C (en) 2012-04-24
HK1093962A1 (en) 2007-03-16
CN100480232C (zh) 2009-04-22
ES2361518T3 (es) 2011-06-17
PL1708987T3 (pl) 2011-08-31
EP1708987B1 (de) 2011-03-16
IL176280A (en) 2010-12-30
PT1708987E (pt) 2011-05-31
EA200601402A1 (ru) 2006-12-29
AU2005211458A1 (en) 2005-08-18
US20080015258A1 (en) 2008-01-17
KR101122173B1 (ko) 2012-03-15
JP2007519661A (ja) 2007-07-19
BRPI0507150A (pt) 2007-06-26
WO2005075408A1 (en) 2005-08-18
EP1708987A1 (de) 2006-10-11
IL176280A0 (en) 2006-10-05
JP4646922B2 (ja) 2011-03-09
ITMI20040145A1 (it) 2004-04-30
SI1708987T1 (sl) 2011-06-30

Similar Documents

Publication Publication Date Title
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
NO20092611L (no) Krystallinsk faststoff Rasagilin base
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
CY1106579T1 (el) Μεθοδος για την παρασκευη συμπλοκων 1,2-διαμινοκυκλοεξανιου-δισθενους πλατινης
BRPI0415164A (pt) dispositivo para administrar uma composição bioterapêutica, composição bioterapêutica, método de preparação de uma composição bioterapêutica, método de tratamento, e dispensador
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
IN2012DN03844A (de)
MX2007003897A (es) Una formulacion farmaceutica que comprende insulina cristalina e insulina disuelta.
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
EA200501818A1 (ru) Индазолы, обладающие анальгетической активностью
DK1708987T3 (da) L-(-)-moprolol-L-(+)-tartrat
ITTO20030850A1 (it) Procedimento per la preparazione di 4-ammino-3,5-dicloro-benzotrifloruro.
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
EA200601117A1 (ru) Малеат ибопамина, способ его получения и фармацевтические композиции на его основе
UA91203C2 (ru) Новая фармацевтическая композиция, применимая для вакцин
UA67614A (en) Antistress substance
UA11051U (uk) Спосіб проведення анестезії
TW200617170A (en) Ready-for-complexation composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1708987

Country of ref document: EP